두경부암 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 약제 클래스, 유통 채널, 지역별, 경쟁(2021-2031년)

The global market for head and neck cancer drugs is projected to expand significantly, rising from USD 2.02 billion in 2025 to USD 2.89 billion by 2031, at a compound annual growth rate of 6.15%. This specialized sector encompasses chemotherapies, immunotherapies, and targeted inhibitors used to treat malignancies in areas such as the oral cavity, pharynx, larynx, and paranasal sinuses. Key drivers of this growth include the increasing worldwide incidence of squamous cell carcinomas, often linked to tobacco and alcohol use, the growing adoption of immune checkpoint inhibitors, and the approval of effective combination therapies. Government efforts to improve early cancer detection also contribute to market expansion. However, the market faces significant hurdles, primarily the high cost of new biological treatments, which restricts access in developing regions and is compounded by strict reimbursement policies that hinder the broad commercialization of innovative drugs. The substantial clinical need is evident, with an estimated 72,680 individuals in the United States alone projected to be diagnosed with major head and neck cancer types in 2025, highlighting the critical demand for effective therapies despite existing financial barriers.

Market Driver

The market's growth is fundamentally fueled by the rising global incidence of head and neck squamous cell carcinoma, largely driven by increasing HPV-induced malignancies and sustained tobacco use. This escalating patient population, which globally saw approximately 947,211 new cases annually according to the National Institutes of Health in September 2025, creates an urgent need for widespread therapeutic solutions in all economies. Simultaneously, rapid advancements in immunotherapy and targeted drug development are transforming treatment paradigms, shifting away from traditional chemotherapy towards more precise biological agents. Immune checkpoint inhibitors, for instance, have significantly improved outcomes for recurrent and metastatic disease, leading to high clinical adoption and substantial commercial success, as exemplified by Merck's Keytruda, which reported quarterly sales of $8.1 billion in October 2025 for its role in head and neck cancer treatment. Despite these innovations, the persistent mortality rates, with an estimated 16,680 deaths in the U.S. in 2025 from these malignancies according to the American Association for Cancer Research, continue to drive demand for further innovation.

Market Challenge

A significant impediment to the global head and neck cancer drugs market is the prohibitive cost of novel biological treatments and immunotherapies. This financial strain severely limits patient access, especially in developing healthcare systems with constrained public funding, and complicates coverage even in developed nations due to stringent reimbursement policies. Such high pricing delays the broad commercial adoption of premium drugs, leading to reduced revenue conversion rates as manufacturers struggle to penetrate cost-sensitive markets and effectively narrowing the target patient base. This economic barrier creates a critical gap between the urgent clinical demand for effective therapies and the actual market penetration of these drugs, as patients' inability to afford life-extending treatments results in lower prescription volumes and stifled market valuation. The estimated 16,680 deaths from head and neck cancers in the U.S. in 2025, as reported by the American Association for Cancer Research, further highlights this market failure: despite a substantial mortality burden demanding robust therapeutic solutions, the high cost of available drugs prevents the market from fully addressing this critical need.

Market Trends

Current market trends are characterized by two significant innovations: the emergence of mRNA-based cancer vaccines and advancements in Antibody-Drug Conjugate (ADC) development. mRNA vaccine technology is increasingly employed by pharmaceutical developers, particularly for viral-associated malignancies like HPV-driven tumors, to train the immune system to target specific oncoproteins, aiming to reduce recurrence in advanced cases and foster personalized immunotherapies. An example of this is the AHEAD-MERIT trial, announced by NHS England in August 2025, which aims to fast-track over 100 advanced head and neck cancer patients to evaluate the BNT113 mRNA vaccine through collaborations between health systems and biotech firms. Concurrently, ADCs offer powerful alternatives to systemic chemotherapy by precisely delivering cytotoxic payloads directly to tumor cells, utilizing novel antigens highly expressed in squamous cell carcinomas such as Nectin-4 and B7-H3. This precision approach holds promise for patients resistant to platinum-based regimens and checkpoint inhibitors. The investigational ADC CRB-701, for instance, earned FDA Fast Track designation and demonstrated a 40% overall response rate at specific dose levels in a study involving advanced solid tumors, as reported by Targeted Oncology in September 2025, showcasing the clinical potential and regulatory recognition of these next-generation biologics.

Key Market Players

• Merck & Co., Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Astrazeneca Plc.
• Fresenius Medical Care AG & CO. KGAA
• F.Hoffmann-la Roche Ltd.

Report Scope

In this report, the Global Head and Neck Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Head and Neck Cancer Drugs Market, By Drug Class

• Chemotherapy
• Immunotherapy
• Targeted Therapy

Head and Neck Cancer Drugs Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Head and Neck Cancer Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Head and Neck Cancer Drugs Market.

Available Customizations:

Global Head and Neck Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Head and Neck Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Chemotherapy, Immunotherapy, Targeted Therapy)
  • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Head and Neck Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Head and Neck Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Head and Neck Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Head and Neck Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Head and Neck Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Head and Neck Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Head and Neck Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Head and Neck Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Head and Neck Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Head and Neck Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Head and Neck Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Head and Neck Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Head and Neck Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Head and Neck Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Head and Neck Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Head and Neck Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Head and Neck Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Head and Neck Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Head and Neck Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Head and Neck Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. South America Head and Neck Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Head and Neck Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Head and Neck Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Head and Neck Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Head and Neck Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lilly and Company
• 15.3. Bristol-Myers Squibb Company
• 15.4. Astrazeneca Plc.
• 15.5. Fresenius Medical Care AG & CO. KGAA
• 15.6. F.Hoffmann-la Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer